@FiercePharma: Another reason Tresiba uptake is crucial to Novo: Xultophy's blockbuster hopes. FiercePharmaMarketing story | Follow @FiercePharma
@CarlyHFierce: ICYMI: Bayer eyes challenge to oral MS meds with new Betaseron injector. Article | Follow @CarlyHFierce
> Bayer and its advisers are rethinking options for the IPO of the company's plastics unit, scheduled for this Friday; books are still not covered, sources told Reuters Wednesday. Report
> The World Health Organization (WHO) is calling for early treatment with anti-retroviral drugs for HIV patients, a push that could give HIV drugmakers like Gilead ($GILD) and GlaxoSmithKline ($GSK) a boost. Report
> Novartis ($NVS) has issued a voluntary recall of an ADHD drug manufactured in Georgia. More
> Pfizer's ($PFE) Wyeth subsidiary will perform nearly $194 million worth of cleanup work at the American Cyanamid Superfund Site in Bridgewater Township, NJ. Report
> The U.S. Patent and Trademark Office (PTO)'s Patent Trial and Appeal Board has, through the inter partes review system, found two patents on Novartis' Exelon Patch to be unpatentable. Release
> Novartis has opened a global data center at its Alcon campus in Fort Worth, TX. More
Medical Device News
@FierceMedDev: Illumina launches solid tumor sequencing panel aimed at Big Pharma researchers. FierceDiagnostics story | Follow @FierceMedDev
@VarunSaxena2: MedImmune licenses 3M compound in hopes of developing intratumorally injected cancer drug. FierceDrugDelivery story | Follow @VarunSaxena2
@EmilyWFierce: OraSure reels in $7.2M from HHS for rapid Ebola test. FierceDiagnostics story | Follow @EmilyWFierce
> Baxter makes nice with activist investor Third Point, offers board seats. Report
> Bard to buy out Medicon, its long-standing Japanese JV with Kobayashi. Article
Biotech News
@FierceBiotech: Fierce's coverage of the Martin Shkreli saga. More | Follow @FierceBiotech
@JohnCFierce: Ladies and gentlemen, the 2015 Fierce 15. Special report | Follow @JohnCFierce
@DamianFierce: Here's what it's like to try to get Sovaldi in my home town. More from The Atlantic | Follow @DamianFierce
> Execs behind Imbruvica raise $75M for a new cancer project. News
> Racing AstraZeneca, Clovis gets a speedy FDA review for its lung cancer drug. Story
> Astellas inks a back-loaded $515M deal to get its hands on a pain drug. Article
Biotech Research News
> The contentious gene editing field gets a tech upgrade. What now? Story
> FDA's 'breakthrough' endorsement carries real weight with the public. Report
> Looking for an alternative to pricey Daraprim? You may be in luck. More
> Researchers zero in on immune system's role in Alzheimer's. Story
> A molecule isolated from the depths of the ocean shows promise in treating AML. Article
Diagnostics News
> Diagnostics companies strike back at CMS lab test rule. More
> OraSure reels in $7.2M from HHS for rapid Ebola test. Item
> Dako to develop companion diagnostic for Pfizer and Merck KGaA's joint cancer candidate. Report
> Illumina launches solid tumor sequencing panel aimed at Big Pharma researchers. Story
> Quest launches patient analytics tool for healthcare providers. Article
Pharma Marketing News
> Roche poised for MS coup with success in hard-to-treat progressive form. Article
> Looking for the next wave of pharma innovation? Try opening the door to more partners, Accenture says. More
> Another reason Tresiba uptake is crucial to Novo: Xultophy's blockbuster hopes. Story
> New Hampshire AG puts pain drug marketing under his microscope. Item
> JAMA: 'Breakthrough' talk in FDA press releases could unfairly sway consumers. Report
And Finally... More than 15 million people enrolled in the top 10 Medicare Part D prescription drug plans will face average premium hikes of 8% in 2016, a new analysis says. More